Evidence map›Paper›PMID 34786733›Full record

ArticleJournal of medical virology2022

Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India.

Urvashi B Singh, Mercy Rophina, Rama Chaudhry, Vigneshwar Senthivel, Kiran Bala, Rahul C Bhoyar, Bani Jolly, Nayer Jamshed, Mohamed Imran, Ritu Gupta and 11 more

Abstract read
In one paragraph

Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Genomic profiles of vaccine breakthrough SARS-CoV-2 strains from Odisha, India.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Urvashi B SinghDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Mercy RophinaCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.
Rama ChaudhryDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.ORCID 0000-0002-7381-1504
Vigneshwar SenthivelCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.
Kiran BalaDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Rahul C BhoyarCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.
Bani JollyCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.
Nayer JamshedDepartment of Emergency Medicine, All India Institute of Medical Sciences, New Delhi, India.
Mohamed ImranCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.
Ritu GuptaDepartment of Laboratory Oncology, All India Institute of Medical Sciences, New Delhi, India.
Praveen AggarwalDepartment of Emergency Medicine, All India Institute of Medical Sciences, New Delhi, India.
Mohit K DivakarCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.ORCID 0000-0002-6731-9249
Subrata SinhaDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
V R ArvindenCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.
Anjali BajajCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.
Afra ShamnathCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.
Abhinav JainCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.
COVID CBNAAT CORE GROUP
Vinod ScariaCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.ORCID 0000-0001-7644-7181
Sridhar SivasubbuCSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.
Randeep GuleriaDepartment of Pulmonary Critical Care & Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India.

Funding

Council of Scientific and Industrial Research (CSIR India) through grants CODEST and MLP2005
6 · The paper itself

Abstract

Emerging reports of SARS-CoV-2 breakthrough infections entail methodical genomic surveillance for determining the efficacy of vaccines. This study elaborates genomic analysis of isolates from breakthrough infections following vaccination with AZD1222/Covishield and BBV152/Covaxin. Variants of concern B.1.617.2 and B.1.1.7 responsible for cases surge in April-May 2021 in Delhi, were the predominant lineages among breakthrough infections.

Indexed as

AdultAgedAged, 80 and overBreakthrough InfectionsChAdOx1 nCoV-19COVID-19COVID-19 VaccinesFemaleGenome, ViralGenomicsHumansIndiaMaleMiddle AgedPhylogenySARS-CoV-2ChAdOx1 nCoV-19COVID-19 VaccinesVaccines, InactivatedCOVID-19genomic analysisSARS-CoV-2vaccine breakthrough infectionsvariants of concern

Identifiers

PMID34786733
PMCPMC8662202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.